Liver-Selective Glucokinase Activators for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents that activate glucokinase in both the pancreas and liver often result in undesirable side effects like hypoglycemia due to excessive insulin secretion, which can lead to pancreatic failure and exacerbate diabetic conditions.
Innovation Solution
Development of compounds that selectively target glucokinase in the liver, avoiding activation in the pancreas to lower blood glucose levels without increasing insulin secretion, thereby preventing hypoglycemia and pancreatic burnout.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucokinase activators are used to lower blood glucose levels, then glucose regulation is improved, but hypoglycemia and pancreatic failure occur due to excessive insulin secretion
Solution Approach 1:
The invention divides the glucokinase activation function into two separate targets: hepatic glucokinase (for glucose regulation) and pancreatic glucokinase (to be avoided). By designing compounds that selectively activate only hepatic glucokinase, the patent segments the previously unified glucokinase activation effect, allowing glucose lowering without triggering excessive insulin secretion that causes hypoglycemia and pancreatic failure.
Solution Approach 2:
The patent applies local quality by creating compounds with differential selectivity for glucokinase isoforms in different tissues. The chemical structures are designed to have high affinity for hepatic glucokinase while showing low affinity for pancreatic glucokinase, thereby concentrating the therapeutic effect in the liver while sparing the pancreas from harmful overstimulation.
2Productivity
If glucokinase activators stimulate insulin secretion to lower blood glucose, then glucose control is enhanced, but pancreatic burnout and disease progression are exacerbated
Solution Approach 1:
The invention extracts the glucose-lowering effect from the insulin-secretion mechanism. By targeting hepatic glucokinase specifically, the compounds lower blood glucose through increased hepatic glucose uptake and metabolism without requiring pancreatic insulin secretion, thereby separating the beneficial glucose control effect from the harmful pancreatic stress.
Solution Approach 2:
The hepatic glucokinase activators serve as an intermediary mechanism that achieves glucose regulation through the liver rather than through pancreatic insulin secretion. This alternative pathway mediates glucose lowering by enhancing hepatic glucose disposal, bypassing the need for pancreatic beta-cell stimulation and thus protecting against pancreatic burnout.
3Reliability
If non-selective glucokinase activators are used, then glucose metabolism is improved, but side effects increase due to lack of tissue specificity
Solution Approach 1:
The patent implements local quality by designing compounds with tissue-specific selectivity. The chemical structures are optimized to interact preferentially with hepatic glucokinase over pancreatic glucokinase, concentrating the metabolic effect in the liver while minimizing off-target effects in the pancreas and other tissues.
Solution Approach 2:
The invention applies parameter changes by modifying molecular properties of glucokinase activators to achieve differential binding affinity. By adjusting structural parameters such as substituent groups and molecular geometry, the compounds achieve high selectivity for hepatic glucokinase, thereby improving the therapeutic index and reducing side effects.
Data Source
AI summary
The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.